Arcus Biosciences Inc
Research Arcus Biosciences Inc (RCUS) on Bullrun: market cap USD 4.01B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRCUS
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.01B
- Financial periodQ2 2026
- RevenueUSD 41.00M
- Net income-USD 91.00M
- Free cash flow-USD 119.00M
Valuation Snapshot
latest market cap is USD 4.01B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 33.00M | -USD 353.00M | -USD 484.00M | n/a | -3.29 | USD 222.00M | USD 99.00M | USD 631.00M |
| FY2024 | USD 51.00M | -USD 283.00M | -USD 176.00M | n/a | -3.14 | USD 150.00M | USD 48.00M | USD 485.00M |
| FY2023 | USD 37.00M | -USD 307.00M | -USD 330.00M | n/a | -4.15 | USD 127.00M | USD 0 | USD 462.00M |
| FY2022 | USD 38.00M | -USD 267.00M | USD 432.00M | n/a | -3.71 | USD 206.00M | USD 3.00M | USD 657.00M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.01B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.99B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.37B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.43B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.50B | 22.2 | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.86B | 96.4 | n/a | n/a |
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Arcus Biosciences Inc's market cap?
Arcus Biosciences Inc's market capitalization is USD 4.01B.
What does Arcus Biosciences Inc do?
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.